1. Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO. Ameloblastoma: current etiopathological concepts and management. Oral Dis. 2018;24:307-16.

https://doi.org/10.1111/odi.12646

PMid:28142213 

2. Vered M, Wright JM. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Odontogenic and Maxillofacial Bone Tumours. Head Neck Pathol. 2022;16:63-75.

https://doi.org/10.1007/s12105-021-01404-7

PMid:35312978 PMCid:PMC9019005

3. Hendra FN, Van Cann EM, Helder MN, Ruslin M, de Visscher JG, Forouzanfar T, et al. Global incidence and profile of ameloblastoma: A systematic review and meta-analysis. Oral Dis. 2020;26:12-21.

https://doi.org/10.1111/odi.13031

PMid:30614154 

4. Ghai S. Ameloblastoma: An Updated Narrative Review of an Enigmatic Tumor. Cureus. 2022;14:e27734.

https://doi.org/10.7759/cureus.27734

PMID: 36127985

5. Mamat Yusof MN, Ch'ng ES, Radhiah Abdul Rahman N. BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14:5593.

https://doi.org/10.3390/cancers14225593

PMid:36428683 PMCid:PMC9688909

6. Garnett M, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6:313-9.

https://doi.org/10.1016/j.ccr.2004.09.022

PMid:15488754 

7. Ritterhouse LL, Barletta JA. BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol. 2015;32:400-8.

https://doi.org/10.1053/j.semdp.2015.02.010

PMid:25744437 

8. da Silva Marcelino BMR, Parise GK, do Canto AM, Sassi LM, Sarmento DJS, Costa ALF, et al. Comparison of Immunohistochemistry and DNA Sequencing for BRAF V600E Mutation Detection in Mandibular Ameloblastomas. Appl Immunohistochem Mol Morphol. 2021;29:390-93.

https://doi.org/10.1097/PAI.0000000000000904

PMid:33443847 

9. do Canto AM, da Silva Marcelino BMR, Schussel JL, Wastner BF, Sassi LM, Corrêa L, et al. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas. Clin Oral Investig. 2019;23:779-84.

https://doi.org/10.1007/s00784-018-2494-y

PMid:29855709 

10. Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res. 2014;20:5517-26.

https://doi.org/10.1158/1078-0432.CCR-14-1069

PMid:24993163 

11. Heikinheimo K, Huhtala JM, Thiel A, Kurppa KJ, Heikinheimo H, Kovac M, et al. The Mutational Profile of Unicystic Ameloblastoma. J Dent Res. 2019;98:54-60.

https://doi.org/10.1177/0022034518798810

PMid:30216733 

12. Kunmongkolwut S, Chaisuparat R. Analysis of BRAF V600E expression and disease-free survival in patients with ameloblastoma. Int J Oral Maxillofac Surg. 2022;51:1034-42.

https://doi.org/10.1016/j.ijom.2021.12.011

PMid:34998647 

13. Lapthanasupkul P, Laosuk T, Ruangvejvorachai P, Aittiwarapoj A, Kitkumthorn N. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;132:e180-e185.

https://doi.org/10.1016/j.oooo.2020.06.002

PMid:32665205 

14. Derakhshan S, Aminishakib P, Karimi A, Saffar H, Abdollahi A, Mohammadpour H, et al. High frequency of BRAF V600E mutation in Iranian population ameloblastomas. Med Oral Patol Oral Cir Bucal. 2020;25:e502-e507.

https://doi.org/10.4317/medoral.23519

PMid:32388526 PMCid:PMC7338065

15. Mendez LD, Wolsefer NS, Asa SL, Wasman J, Yoest JM, Stojanov IJ. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. Mod Pathol. 2022;35:1570-77.

https://doi.org/10.1038/s41379-022-01105-8

PMid:35676332 

16. Owosho AA, Ladeji AM, Adebiyi KE, Olajide MA, Okoye ISI, Kehinde T, et al. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution. Eur Arch Otorhinolaryngol. 2021;278:3065-71.

https://doi.org/10.1007/s00405-020-06491-w

PMid:33231757 

17. Bashir N, Asif M, Malik IS, Araa N, Rashid F, Uddin H, et al. Frequency of Expression of BRAF V600E and Epidermal Growth Factor Receptor (EGFR) in Ameloblastoma. Asian Pacific Journal of Cancer Biology. 2022.

https://doi.org/10.31557/apjcb.2022.7.1.29-35

PMid:

18. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014;46:722-5.

https://doi.org/10.1038/ng.2986

PMid:24859340 PMCid:PMC4418232

19. Mamat Yusof MN, Ch'ng ES, Radhiah Abdul Rahman N. BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14:5593.

https://doi.org/10.3390/cancers14225593

PMid:36428683 PMCid:PMC9688909

20. Fregnani ER, Perez DE, Paes de Almeida O, Fonseca FP, Soares FA, Castro-Junior G, et al. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Histopathology. 2017;70:473-84.

https://doi.org/10.1111/his.13095

PMid:27681305 

21. Santana LADM, Santana EMR, Albuquerque-Júnior RLC, Takeshita WM, Braga Pereira N, Gomez RS, et al. Ameloblastoma shows nuclear BAP1 immunoexpression, independently of the BRAF V600E status. Oral Dis. 2021;27:1238-42.

https://doi.org/10.1111/odi.13644

PMid:32945606 

22. Togni L, Zizzi A, Mazzucchelli R, Santarelli A, Rubini C, Mascitti M. Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis. Int J Oral Sci. 2022;14:22.

https://doi.org/10.1038/s41368-022-00170-8

PMid:35468886 PMCid:PMC9038922

23. Awadalkreem F, Abdoun O. Enucleation and surgical stent as a treatment strategy for a large unicystic ameloblastoma: Case report and review of literature. Int J Surg Case Rep. 2020;77:371-77.

https://doi.org/10.1016/j.ijscr.2020.11.025

PMid:33217656 PMCid:PMC7683291

24. Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014;232:492-98.

https://doi.org/10.1002/path.4317

PMid:24374844 PMCid:PMC4255689

25. Diniz MG, Gomes CC, Guimarães BV, Castro WH, Lacerda JC, Cardoso SV, et al. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumour Biol. 2015;36:5649-53.

https://doi.org/10.1007/s13277-015-3238-0

PMid:25854168 

26. Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology. 2014;46:509-17.

https://doi.org/10.1097/PAT.0000000000000119

PMid:25014730 PMCid:PMC4233678

27. Mendez LD, Wolsefer NS, Asa SL, Wasman J, Yoest JM, Stojanov IJ. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. Mod Pathol. 2022;35:1570-77.

https://doi.org/10.1038/s41379-022-01105-8

PMid:35676332 

28. Ji YD, Johnson DN, Faquin WC, Peacock ZS. Utility of BRAF V600E immunohistochemistry in the diagnosis of mandibular ameloblastomas. Int J Oral Maxillofac Surg. 2024; 53:122-26.

https://doi.org/10.1016/j.ijom.2023.06.001

PMid:37344275 

29. Oh KY, Cho SD, Yoon HJ, Lee JI, Hong SD. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies. J Oral Pathol Med. 2021;50:85-91.

https://doi.org/10.1111/jop.13108

PMid:32939809 

30. Shi HA, Ng CWB, Kwa CT, Sim QXC. Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies. Surgeon. 2021;19:238-43.

https://doi.org/10.1016/j.surge.2020.06.009

PMid:32712102